Overview

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC.

Status:
Recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

To compare a complex induction multimodality protocol (ESPATUE) + concurrent immunotherapy with PD-L1 antibody Durvalumab given every three weeks to the same induction multimodality protocol without Durvalumab immunotherapy induction followed by definitive local treatment (surgery for those considered resectable or chemoradiation boost for those not considered to be R0-resectable) followed by consolidation Durvalumab treatment in both arms.

Phase:

Phase 2

Details

Lead Sponsor:

University Hospital, Essen

Treatments:

Antibodies, Monoclonal
Durvalumab